有效的非小细胞肺癌治疗的基础-Nicholas Thatcher-2009CSCO年会精选.pptVIP

salvage slides Building?the?foundations?of?effective?NSCLC?therapy Prof. Nicholas Thatcher Christie Hospital NHS Trust, U.K. AVASTIN FIRST LINE NON-SQUAMOUS ADVANCED NSCLC Introduction, anti angiogenesis Phase III trials, E4599, AVAIL Phase IV trial, SAIL Future Conclusion ANGIOGENESIS INHIBITION THROUGH THE VEGF PATHWAY ANTI-VEGF THERAPY: MECHANISM OF ACTION EFFECTS OF VEGF INHIBITION:inhibition of recurrent vessel growth PIVOTAL STUDIES OF AVASTIN IN COMBINATION WITH PLATINUM-CONTAINING CHEMOTHERAPY PHASE III TRIALS OF AVASTIN (E4599 VS. AVAIL): ELIGIBILITY CRITERIA AND SAFETY E4